KA
Therapeutic Areas
Altimmune Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Pemvidutide (ALT-801) | Obesity | Phase 2 |
| HepTcell | Chronic Hepatitis B | Phase 2 |
| NasoVAX | Influenza | Phase 2 |
Leadership Team at Altimmune
VK
Vipin K. Garg, Ph.D.
President, Chief Executive Officer, and Director
RE
Richard Eisenstadt
Chief Financial Officer
SH
Scott Harris, M.D.
Chief Medical Officer
CL
Cynthia L. Bens
Senior Vice President, Investor Relations & Corporate Communications
R(
Raymond (Ray) T. Jones
Senior Vice President, Commercial
DJ
Dr. John B. Bode, J.D.
Senior Vice President, Corporate Development & General Counsel
E(
Elizabeth (Bess) G. Weatherman
Chairman of the Board of Directors
DT
Dr. Timothy D. Barberich
Director
DW
Dr. William (Bill) J. Enright
Director
DJ
Dr. John P. Richard
Director